FOUNDER & CHAIRMAN OF THE BOARD
Minna is the leading inventor of DiagMMR® with more than 25 years of experience in the field of Lynch syndrome research and has had an active role in both the identification of the LS related genes and mutations as well as the bettering of LS recognition with more than 60 scientific publications in the field. Minna is also an active member of the International Society for Gastrointestinal Hereditary Tumours, InSiGHT.
CHIEF EXECUTIVE OFFICER
Niklas is responsible for operational and financial management, investor relations, and shareholder management. He is a corporate finance professional with a background in M&A and capital restructurings. Niklas joined LSCD in 2017 as the CFO and was appointed as CEO in 2022.
CHIEF BUSINESS OFFICER
Philippe brings a wealth of experience from corporate roles in major blue-chip companies on an international level in Europe and the Americas, with responsibilities for strategy development, change management, procurement and logistics. He is responsible for commercial partnerships, international expansion, marketing & communications, strategic planning.
CHIEF SCIENTIFIC OFFICER
Minttu has worked on Lynch syndrome research in Prof. Nyström ́s lab for over 10 years and is a co-inventor of DiagMMR®. Her doctoral thesis, “Recognizing Lynch syndrome by DNA mismatch repair deficiency” focused on pathogenicity assessment and interpretation of LS associated mutations and functional detection of reduced mismatch repair. She is responsible for scientific research, product development, and laboratory management.
Jaana has vast experience in cell culture and works to ensure the meticulous handling of patient samples from sampling to testing. In addition to coordinating the sample handling and running the cell culture processes, she assists with other processes of the DiagMMR® testing and is responsible for quality management.
Saara is responsible for the laboratory production of the DiagMMR® assay and result interpretation. Saara has a PhD degree in mitochondrial disease field and more than 10 years of experience in metabolic research. Saara has routinely handled invaluable samples, and she is experienced in variety of molecular and biochemical techniques and data analysis.
Anu has extensive and versatile laboratory work experience, particularly in cell culture and molecular techniques. She supports the daily laboratory operations at LS CancerDiag and participates in DiagMMR® sample handling.
Tea is currently doing her Master’s studies in Genetics and Molecular Biosciences. In her Bachelor’s thesis she investigated how red and processed meat play a part in increasing the risk of colorectal cancer. She joined us as a part-time worker and is keen to learn more about hereditary colorectal cancer.
Mikael recently graduated from the Master’s Programme in Genetics and Molecular Biosciences from the University of Helsinki. In his master’s thesis, Mikael studied the effects of decreased MLH1 expression on gene expression and cellular functions. Currently Mikael is designing an R&D project and assists with cell culturing.
LS CancerDiag has launched a funding round in collaboration with Springvest.
The company aims to raise €5.4M in capital to support the expansion into the United States and introduce DiagMMR® to the largest health care market in the world.